Biodistribution of GB-10 (Na2 10B10H10) compound for boron neutron capture therapy (BNCT) in an experimental model of oral cancer in the hamster cheek pouch
Biodistribution of GB-10 (Na2 10B10H10) compound for boron neutron capture therapy (BNCT) in an experimental model of oral cancer in the hamster cheek pouch
复制标题
DOI：
10.1016/j.archoralbio.2003.10.003
复制
发表时间：
2004-04-01
影响因子：
3
通讯作者：
Schwint, AE
中科院分区：
文献类型：
--
作者：
Heber, E;Trivillin, VA;Schwint, AE
目的：我们先前提出了口腔癌的仓鼠颊囊模型用于BNCT研究。我们在此介绍了无毒硼化合物GB-10（（Na 2 B 10 H 10）-B-10）在该模型中的生物分布，以评估其用于BNCT或BNCT增强快中子治疗的潜力。材料与方法：我们评估了GB-10在肿瘤和癌前组织以及潜在剂量限制性临床相关正常组织中的摄取和保留。结果如下：通过GB-10（50 mg B/kg）递送的平均肿瘤硼浓度在给药后20 min达到峰值77.7 +/- 28.0 ppm，并在3 h时保持在治疗有用值31.9 +/- 21.4 ppm。正常组织的清除率比肿瘤组织快。持续较低的脑和脊髓值将排除正常组织毒性。癌前组织对GB-10的摄取可能在野外癌变区域的治疗中具有潜在的用途。GB-10在不同的肿瘤区域均匀沉积，这是治疗异质性肿瘤的一个优势。提示BPA与GB-10联合应用可提高BNCT的疗效。结论：GB-10是一种有潜力的头颈部肿瘤BNCT和BNCT-FNT的硼载体。(C)2003 Elsevier Ltd.保留所有权利。
Objective: We previously proposed the hamster cheek pouch model of oral cancer for BNCT studies. We herein present the biodistribution of a non-toxic boron compound, GB-10 ((Na2B10H10)-B-10), in this model to assess its potential for BNCT or BNCT enhanced Fast Neutron Therapy. Materials and methods: We evaluated the uptake and retention of GB-10 in tumour and precancerous tissue and in potentially dose-limiting, clinically relevant normal tissues. Results: Mean tumour boron concentration delivered by GB-10 (50 mg B/kg) peaked to 77.7 +/- 28.0 ppm at 20 min post-ad ministration and remained at therapeutically useful values of 31.9 +/- 21.4 ppm at 3 h. The clearance rate for normal tissues was faster than for tumour tissue. The consistently low brain and spinal cord values would preclude normal tissue toxicity. The uptake of GB-10 by precancerous tissue may be of potential use in the treatment of field cancerized areas. GB-10 was deposited homogeneously in different tumour areas, an asset when treating heterogenous tumours. The data suggests that the joint administration of BPA and GB-10 may improve the therapeutic efficacy of BNCT. Conclusions: GB-10 is a potential boron carrier for BNCT of head and neck tumours and for BNCT-FNT. (C) 2003 Elsevier Ltd. All rights reserved.